Monitoring Osteoporosis Therapy With Bone Densitometry: Misleading Changes and Regression to the Mean
Article Abstract:
Doctors should not discontinue alendronate or raloxifene if women who take either drug lose bone mass. Both drugs are used by postmenopausal women to prevent bone loss. Researchers analyzed data from two studies of over 6,000 postmenopausal women, some of whom took alendronate, some of whom took raloxifene, and some of whom took a placebo. Women who lost bone during the first year of treatment were likely to gain bone mass during the second year. Conversely, women who gained bone mass the first year often lost bone mass the second year.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
Phytoestrogen supplements for the treatment of hot flashes: a randomized controlled trial
Article Abstract:
Two alternative treatments for menopause may not be very effective, according to a study of 246 women who kept a daily diary during the study. Neither Promensil nor Rimostil was any better than a placebo, or inactive substance, in reducing the number of hot flashes. Both of these products contain red clover, which is a source of isoflavones.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial
Article Abstract:
The drug raloxifene appears to lower the risk of breast cancer in postmenopausal women. Raloxifene has properties that mimic estrogen or block the action of estrogen depending on the organ. Researchers randomly assigned 7,705 postmenopausal women to take raloxifene or a placebo and then followed the women for at least three years. The drug was used to prevent bone fractures because all the women had osteoporosis. After three years, raloxifene reduced the risk of breast cancer by 76%.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Effect of Estrogen on Brain Activation Patterns in Postmenopausal Women During Working Memory Tasks. Estrogen and Alzheimer Disease Plausible Theory, Negative Clinical Trial
- Abstracts: Morbidity and mortality in breastfed and formula-fed infants of HIV-1-infected women: A randomized clinical trial. (ORIGINAL CONTRIBUTION)
- Abstracts: Dietary patterns in six European populations: Results from EURALIM, a collaborative European data harmonization and information campaign